Trial ID or NCT#

NCT03582124

Status

not recruiting iconNOT RECRUITING

Purpose

This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Official Title

A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Natalie Shaubie Lui
Natalie Shaubie Lui
Thoracic surgeon
Assistant Professor of Cardiothoracic Surgery (Thoracic Surgery) at the Stanford University Medical Center
Eben Rosenthal
Eben Rosenthal
Otolaryngologist, Head and neck surgeon
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiology (Molecular Imaging Program at Stanford)

Contact us to find out if this trial is right for you.

CONTACT

Roan Courtney Raymundo
(650) 721-4071